Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling

被引:21
作者
Lu, Minan [1 ,2 ]
Xie, Kegong [2 ]
Lu, Xianzhe [2 ]
Lu, Lu [2 ]
Shi, Yu [2 ]
Tang, Yujin [1 ,2 ]
机构
[1] Jinan Univ, Dept Orthoped Surg, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China
[2] Youjiang Med Univ Nationalities, Dept Orthoped Surg, Affiliated Hosp, Baise 533000, Guangxi, Peoples R China
关键词
Osteosarcoma; Tumor microenvironment; MSCs; NGR1; Cell proliferation and migration; Drug resistance; PROMOTES; METASTASIS; INHIBITION; ACTIVATION;
D O I
10.1007/s10637-020-01027-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor microenvironment is a critical participant in the initiation, progression and drug resistance of carcinomas, including osteosarcoma. Notoginsenoside R1 (NGR1) is a proverbial active ingredient of the traditional Chinese medicine Panax notoginseng (PN) and possess undeniable roles in several cancers. Nevertheless, its function in osteosarcoma and tumor microenvironment remains elusive. In the current study, exposure to NGR1 dose-dependently inhibited osteosarcoma cell viability and migration, and induced apoptosis. Furthermore, osteosarcoma cells that were incubated with conditioned medium (CM) from bone marrow mesenchymal stem cells (BMSCs) exhibited greater proliferation, migration capacity and MMP-2 and MMP-9 expression relative to control cells, which was reversed when BMSCs were treated with NGR1. Notably, administration with NGR1 antagonized CM-evoked doxorubicin resistance in osteosarcoma cells by decreasing cell viability and increasing cell apoptosis and caspase-3/9 activity. Mechanically, NGR1 suppressed IL-6 secretion from BMSCs, as well as the subsequent activation of the JAK2/STAT3 signaling in osteosarcoma cells. In addition, blocking the JAK2 pathway by its antagonist AG490 reversed CM-induced osteosarcoma cell proliferation, migration and doxorubicin resistance. Moreover, exogenous supplementation with IL-6 engendered not only the reactivation of the JAK2/STAT3 signaling but also muted NGR1-mediated efficacy against osteosarcoma cell malignancy and doxorubicin resistance. Collectively, NGR1 may directly restrain osteosarcoma cell growth and migration, or indirectly antagonize MSC-evoked malignancy and drug resistance by interdicting IL-6 secretion-evoked activation of the JAK2/STAT3 pathway. Consequently, the current study may highlight a promising therapeutic strategy against osteosarcoma by regulating tumor cells and the tumor microenvironment.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 34 条
  • [1] Update on Survival in Osteosarcoma
    Anderson, Megan E.
    [J]. ORTHOPEDIC CLINICS OF NORTH AMERICA, 2016, 47 (01) : 283 - +
  • [2] Cancer prevention and therapy through the modulation of the tumor microenvironment
    Casey, Stephanie C.
    Amedei, Amedeo
    Aquilano, Katia
    Azmi, Asfar S.
    Benencia, Fabian
    Bhakta, Dipita
    Bilsland, Alan E.
    Boosani, Chandra S.
    Chen, Sophie
    Ciriolo, Maria Rosa
    Crawford, Sarah
    Fujii, Hiromasa
    Georgakilas, Alexandros G.
    Guha, Gunjan
    Halicka, Dorota
    Helferich, William G.
    Heneberg, Petr
    Honoki, Kanya
    Keith, W. Nicol
    Kerkar, Sid P.
    Mohammed, Sulma I.
    Niccolai, Elena
    Nowsheen, Somaira
    Rupasinghe, H. P. Vasantha
    Samadi, Abbas
    Singh, Neetu
    Talib, Wamidh H.
    Venkateswaran, Vasundara
    Whelan, Richard L.
    Yang, Xujuan
    Felsher, Dean W.
    [J]. SEMINARS IN CANCER BIOLOGY, 2015, 35 : S199 - S223
  • [3] Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
    Chen, Dar-Ren
    Lu, Dah-Yuu
    Lin, Hui-Yi
    Yeh, Wei-Lan
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [4] Effects of notoginsenoside R1 on hepatic microcirculation disturbance induced by gut ischemia and reperfusion
    Chen, Wei-Xing
    Wang, Fang
    Liu, Yu-Ying
    Zeng, Qing-Jiang
    Sun, Kai
    Xue, Xin
    Li, Xiang
    Yang, Ji Ying
    An, Li-Hua
    Hu, Bai-He
    Yang, Jin-Hui
    Wang, Chuan-She
    Li, Zhi-Xin
    Liu, Lian-Yi
    Li, Yan
    Zheng, Jun
    Liao, Fu-Long
    Han, Dong
    Fan, Jing-Yu
    Han, Jing-Yan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (01) : 29 - 37
  • [5] Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion
    Cortini, Margherita
    Massa, Annamaria
    Avnet, Sofia
    Bonuccelli, Gloria
    Baldini, Nicola
    [J]. PLOS ONE, 2016, 11 (11):
  • [6] A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion
    Fontanella, Raffaela
    Pelagalli, Alessandra
    Nardelli, Anna
    D'Alterio, Crescenzo
    Ierano, Caterina
    Cerchia, Laura
    Lucarelli, Enrico
    Scala, Stefania
    Zannetti, Antonella
    [J]. CANCER LETTERS, 2016, 370 (01) : 100 - 107
  • [7] IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
    Gross, Amy C.
    Cam, Hakan
    Phelps, Doris A.
    Saraf, Amanda J.
    Bid, Hemant K.
    Cam, Maren
    London, Cheryl A.
    Winget, Sarah A.
    Arnold, Michael A.
    Brandolini, Laura
    Mo, Xiaokui
    Hinckley, John M.
    Houghton, Peter J.
    Roberts, Ryan D.
    [J]. JCI INSIGHT, 2018, 3 (16):
  • [8] Hall B., 2007, V180, P263
  • [9] SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells
    Han, Xiuxin
    Liu, Fengting
    Zhang, Chao
    Ren, Zhiwu
    Li, Lili
    Wang, Guowen
    [J]. BIOLOGICAL CHEMISTRY, 2019, 400 (04) : 545 - 553
  • [10] Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?
    Hattinger, Claudia M.
    Fanelli, Marilu
    Tavanti, Elisa
    Vella, Serena
    Riganti, Chiara
    Picci, Piero
    Serra, Massimo
    [J]. FUTURE ONCOLOGY, 2017, 13 (08) : 673 - 677